Swiss ProspectivE Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study

ClinicalTrials.gov ID

NCT06774053

Lead Sponsor

University Hospital, Basel, SwitzerlandOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

600Estimated

Last Update Posted

Jun 30, 2026Actual

Start Date

Apr 20, 2026Actual

Primary Completion Date

Jan 2046Estimated

Completion Date

Jan 2046Estimated

Official Title

Swiss Prospective Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study

Brief Summary

The goal of this observational study is to understand the factors influencing the well-being and health of transgender and gender-diverse (TGD) individuals undergoing gender-affirming therapies in Switzerland. The study population includes TGD individuals aged 16 and older, at various stages of their medical transition, including those who have discontinued or detransitioned.

The main question is:

What are the key factors influencing the well-being and health outcomes of transgender and gender-diverse individuals undergoing gender-affirming therapies?

Researchers will compare health outcomes across different subgroups, such as those at different stages of transition or detransition, to examine the effects of gender-affirming therapies.

Participants will:

Complete electronic questionnaires assessing gender congruence, quality of life, mental health, and other outcomes.

Provide biological samples (e.g., blood, urine, stool, and skin swabs) for laboratory analysis.

Undergo clinical evaluations related to endocrinology, fertility, dermatology, and urology as part of their routine follow-up.

• Transgender Individuals
• Gender Incongruence

• Group A (start of GAHT)
• Group B (on-going GAHT)
• Group C (GAS)

Ages Eligible for Study

Child (0-17)Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age 16 years and above.
• Established diagnosis of gender incongruence
• Indication for gender affirming therapy or ongoing or discontinued gender affirming therapy

Exclusion Criteria:

• Unable to give informed consent
• Missing commitment or ability to study protocol adherence

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

University Hospital, Basel, SwitzerlandOTHER

Collaborators

University Hospital, ZürichOTHER

Cantonal Hospital Lucerne, SwitzerlandUNKNOWN

lea.slahor@luks.ch+41 205 51 03

bettina.winzeler@usb.ch+41 44 255 36 20

• Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content

  NCT06291675

  RecruitingObservationalUpdated Sep 26, 2025
• The Effect of Gender-affirmative Measures on Breast Perception in Trans Men

  NCT07252687

  RecruitingObservationalUpdated Mar 6, 2026
• Effects of Gender-Affirming Hormone Therapy on Cardiovascular, Metabolic, and Mental Health Outcomes in Transgender Adults.

  NCT07394400

  Not yet recruitingObservationalUpdated Feb 6, 2026
• China Gender-affirming Hormone Therapy Study

  NCT05318755

  RecruitingObservationalUpdated Nov 7, 2024
• Effects of Gender-affirming Hormone Therapy on Transgender People

  NCT06022562

  CompletedObservationalUpdated Aug 22, 2025
• i2TransHealth: Interdisciplinary, Internet-based Trans Health Care

  NCT04290286

  CompletedInterventionalNot ApplicableUpdated Nov 4, 2022